R. Saran, et al., “Longer treatment time and slower ultrafiltration in hemodialysis: Associations with reduced mortality in the DOPPS,” Kidney International, Vol. 69 No. 7, pp. 1222–1228, April 2006.

has been cited by the following article:

• TITLE: End Stage Renal Disease Economics and the Balance of Treatment Modalities

  AUTHORS: John D. Sullivan

  KEYWORDS: End Stage Renal Disease, Dialysis, Medicare, Reimbursement, Economics, Mergers, Acquisitions

  JOURNAL NAME: Journal of Service Science and Management, Vol.3 No.1, March 29, 2010

  ABSTRACT: Periodically, research articles emerge arguing the economic benefits of peritoneal dialysis, or PD, over the traditional in-center hemo dialysis for patients suffering from End Stage Renal Disease. Resulting conclusions indentify PD as the ideal therapy to reduce Medicare expenditures for this expensive treatment. However, despite this possible economic benefit to the United States taxpayer, the number of PD patients remains relatively flat with an increasing amount of patients being prescribed in-center hemo dialysis. A simplistic view of controlling the rising costs, on a per treatment basis, associated with the treatment of this disease would be to increase the number of patients from in-center hemo dialysis to peritoneal dialysis. This paper will argue why this shift is both unlikely and unrealistic, and why the resulting potential cost savings to this segment of the Medicare program is a myth.